Assignment phamacotherpy for cardiovasular disorder/respirtory

..heart disease remains the No. 1 killer in America; nearly half of all Americans have high blood pressure, high cholesterol, or smokeïme of the leading risk factors for heart disease/p>

urphy et al., 2018

Despite the high mortality rates associated with cardiovascular disorders, improved treatment options do exist that can help address those risk factors that afflict the majority of the population today.

As an advanced practice nurse, it is your responsibility to recommend appropriate treatment options for patients with cardiovascular disorders. To ensure the safety and effectiveness of drug therapy, advanced practice nurses must consider aspects that might influence pharmacokinetic and pharmacodynamic processes such as medical history, other drugs currently prescribed, and individual patient factors.

Reference: Murphy, S. L., Xu, J., Kochanek, K. D., & Arias, E. (2018). Mortality in the United States, 2017. Retrieved from https://www.cdc.gov/nchs/products/databriefs/db328.htm

To Prepare

Review the Resources for this module and consider the impact of potential pharmacotherapeutics for cardiovascular disorders introduced in the media piece.
Review the case study assigned by your Instructor for this Assignment.
Select one the following factors: genetics, gender, ethnicity, age, or behavior factors.
Reflect on how the factor you selected might influence the patientàpharmacokinetic and pharmacodynamic processes.
Consider how changes in the pharmacokinetic and pharmacodynamic processes might impact the patientàrecommended drug therapy.
Think about how you might improve the patientàdrug therapy plan based on the pharmacokinetic and pharmacodynamic changes. Reflect on whether you would modify the current drug treatment or provide an alternative treatment option for the patient.

case study:

CASE STUDY 2: Patient HM has a history of atrial fibrillation and a transient ischemic attack (TIA). The patient has been diagnosed with type 2 diabetes, hypertension, hyperlipidemia and ischemic heart disease.

Drugs currently prescribed include the following:

arfarin 5 mg po daily MWF and 2.5 mg daily T, TH, Sat, Sun

spirin 81 mg po daily

etformin 1000 mg po bid

lyburide 10 mg po bid

tenolol 100 mg po daily

otrin 200 mg 1àtablets every 6 hours as needed for pain

Write a 2- to 3-page paper that addresses the following:

Explain how the factor you selected might influence the pharmacokinetic and pharmacodynamic processes in the patient from the case study you were assigned.
Describe how changes in the processes might impact the patientàrecommended drug therapy. Be specific and provide examples.
Explain how you might improve the patientàdrug therapy plan and explain why you would make these recommended improvements.

Rubrics:

Explain how the factor you selected might influence the pharmacokinetic and pharmacodynamic processes in the patient from the case study you were assigned.–

Describe how changes in the processes might impact the patient’s recommended drug therapy. Be specific and provide examples.–

Explain how you might improve the patient’s drug therapy plan, and explain why you would make these recommended improvements.

Written Expression and Formatting – Paragraph Development and Organization:
Paragraphs make clear points that support well developed ideas, flow logically, and demonstrate continuity of ideas. Sentences are carefully focused–neither long and rambling nor short and lacking substance.

Written Expression and Formatting – English writing standards:
Correct grammar, mechanics, and proper punctuation

Written Expression and Formatting – The paper follows correct APA format for title page, headings, font, spacing, margins, indentations, page numbers, running head, parenthetical/in-text citations, and reference list.–

References:

Rosenthal, L. D., & Burchum, J. R. (2018). Lehneàpharmacotherapeutics for advanced practice providers. St. Louis, MO: Elsevier.

Chapter 34, ¥view of Hemodynamics(pp. 335ô0)
Chapter 35, )uretics(pp. 341ô9)
Chapter 36, 2ugs Acting on the Renin-Angiotensin-Aldosterone System(pp. 351ö2)
Chapter 37, álcium Channel Blockers(pp. 363ö9)
Chapter 38, ¡sodilators(pp. 371÷3)
Chapter 39, 2ugs for Hypertension(pp. 375ø8)
Chapter 40, 2ugs for Heart Failure(pp. 38902)
Chapter 41, ntidysrhythmic Drugs(pp. 40318)
Chapter 42, 2ophylaxis of Atherosclerotic Cardiovascular Disease: Drugs That Help Normalize Cholesterol and Triglyceride Levels(pp. 41939)
Chapter 43, 2ugs for Angina Pectoris(pp. 44150)
Chapter 44, nticoagulant and Antiplatelet Drugs(pp. 45172)

15% turnitin pls